PMV Pharmaceuticals Appoints Philip Herman as Chief Commercial Officer
PMV Pharmaceuticals appointed Philip Herman as Chief Commercial Officer to lead commercial strategy and launch preparation for rezatapopt, its first-in-class p53 reactivator. The company reiterated plans to submit an NDA for accelerated approval of rezatapopt in platinum-resistant/refractory ovarian cancer in the first quarter of 2027, with enrollment in the Phase 2 PYNNACLE trial being completed.
Key figures
- Drug Name
- rezatapopt
- Phase Of Trial
- Phase 2
- Indication
- platinum-resistant/refractory ovarian cancer
- Lead trial
- PYNNACLE
- Approval pathway
- accelerated approval
- Nda submission timing
- first quarter of 2027
- New cco years experience
- 24
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.